Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway

Aleksandra Toloczko1,2, Fusheng Guo1, Hiu-Fung Yuen1, Qing Wen3, Stephen A. Wood4, Yan Shan Ong1, Pei Yi Chan1, Asfa Alli Shaik1, Jayantha Gunaratne1, Mark J. Dunne2, Wanjin Hong1, and Siew Wee Chan1

Abstract

The core LATS kinases of the Hippo tumor suppressor pathway phosphorylate and inhibit the downstream transcriptional co-activators YAP and TAZ, which are implicated in various cancers. Recent studies have identified various E3 ubiquitin ligases that negatively regulate the Hippo pathway via ubiquitination, yet few deubiquitinating enzymes (DUB) have been implicated. In this study, we report the DUB USP9X is an important regulator of the core kinases of this pathway. USP9X interacted strongly with LATS kinase and to a lesser extent with WW45, KIBRA, and Angiomotin, and LATS co-migrated exclusively with USP9X during gel filtration chromatography analysis. Knockdown of USP9X significantly downregulated and destabilized LATS and resulted in enhanced nuclear translocation of YAP and TAZ, accompanied with activation of their target genes. In the absence of USP9X, cells exhibited an epithelial-to-mesenchymal transition phenotype, acquired anchorage-independent growth in soft agar, and led to enlarged, disorganized, three-dimensional acini. YAP/TAZ target gene activation in response to USP9X knockdown was suppressed by knockdown of YAP, TAZ, and TEAD2. Deletion of USP9X in mouse embryonic fibroblasts resulted in significant downregulation of LATS. Furthermore, USP9X protein expression correlated positively with LATS but negatively with YAP/TAZ in pancreatic cancer tissues as well as pancreatic and breast cancer cell lines. Overall, these results strongly indicate that USP9X potentiates LATS kinase to suppress tumor growth.

Introduction

The Hippo pathway is an evolutionarily conserved kinase cascade governing organ size and contact inhibition through regulation of cell proliferation and apoptosis during organ development and regeneration. Dysregulation of this signaling cascade contributes to tumorigenesis. The core components of the pathway consist of upstream regulators, a core kinase cassette, and downstream oncogenes. Once the core kinases are activated, LATS1/2 kinase phosphorylates downstream targets YAP and TAZ, leading to their cytoplasmic retention and inactivation; otherwise, YAP and TAZ translocate into the nucleus through interaction with transcription factor TEAD to activate pro-proliferative and antiapoptotic genes. YAP and TAZ have been shown to be fundamental for cancer initiation and growth of most solid tumors including liver, breast, lung, and pancreatic cancers (1–6).

In most recent reports, key members of the Hippo pathway were revealed to be negatively regulated by ubiquitination. A set of E3 ubiquitin ligases were shown to destabilize LATS1 (7, 8), LATS2 (9), WW45 (10), or AMOT (11), resulting in stimulation of YAP and TAZ activity. Ubiquitination and deubiquitination of proteins play an essential role in the regulation of homeostasis and are increasingly implicated in the onset and progression of various tumors. Nevertheless, little information regarding regulation of the Hippo pathway by deubiquitinating enzymes has been described.

The ubiquitin-specific protease 9X (USP9X/FAM) is a highly conserved member of the ubiquitin-specific proteases (USP) family of deubiquitinating enzymes (12). USP9X is known to play a crucial role in development and disease (13). Recently, more studies emerged implicating this deubiquitinating enzyme in initiation and progression of various cancers. In pancreatic ductal adenocarcinoma, USP9X was found to be the most commonly mutated gene inactivated in over 50% of tumors in a mouse mutagenesis screen of pancreatic cancer and its loss enhanced transformation of pancreatic cancer cells (14). Furthermore, elevated expression of USP9X has been linked to the poor prognosis of patients diagnosed with non–small lung carcinoma (15). Thus, USP9X may play a context-specific role in the progression of human cancers, acting either as a tumor suppressor or an oncprotein. From our Hippo pathway proteomic data, USP9X stands out as one of the high confidence interactors.

Note: Supplemental data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

A. Toloczko and F. Guo contributed equally to this article.

Corresponding Authors: Siew Wee Chan, Institute of Molecular and Cell Biology (IMCB), A*STAR, Singapore, Republic of Singapore. 1School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, United Kingdom. 2Centre for Public Health and Centre for Cancer Research & Cell Biology, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, United Kingdom. 3Eskitis Institute for Drug Discovery, Griffith University, Queensland, Australia.

doi: 10.1158/0008-5472.CAN-16-3413
©2017 American Association for Cancer Research.
In this study, we report the role of USP9X as a positive regulator of the Hippo pathway signaling. We reveal that USP9X interacts strongly with Hippo components LATS, moderately with WW45, to a lesser extent with KIBRA and Angiomotins. Only LATS and USP9X co-migrated strongly in the same fraction of cell lysates separated by FPLC. USP9X stabilizes each of these components and inhibits downstream activation of YAP/TAZ and TEAD. The expression of USP9X is correlated positively with LATS kinases and negatively with YAP/TAZ in pancreatic and breast cancer cells as well as pancreatic cancer patient tissues, indicating that USP9X synergizes the Hippo components to mediate tumor suppressor function.

Materials and Methods

Cell culture
Normal human pancreatic ductal epithelial (HPDE6) cell line was a kind gift from Dr. Ming-Sound Tsao (Princess Margaret Cancer Centre, UHN, Canada). HPDE6 cells were cultured in keratinocyte serum free (KSF) medium supplemented with epidermal growth factor and bovine pituitary extract (Gibco Life Technologies). All the rest of the cell lines were purchased from ATCC (after year 2010) with cell authentication and mycoplasma tests. The cell authentication tests were last performed by DNA Sequencing Facility of the Institute of Molecular and Cell Biology, Singapore, using Promega GenePrint 10 System in July 2017 and had >90% match with ATCC database. All the cell lines in the lab are routinely tested every 6 months for mycoplasma using Lonza MycoAlert Mycoplasma Detection Kit and last mycoplasma tests were performed in July 2017. The cells described in the experiments were used within 10 passages after thawing from the original vials. The three-dimensional culture of MCF10A mammary epithelial acini was performed exactly as outlined previously (16). Fibroblasts were isolated from day 14.5 mouse embryos following mating of Usp9x<sup>fl</sup>/<sup>fl</sup> females to Usp9x<sup>fl</sup>/<sup>fl</sup> males (17), and cultured as described (18). Animal studies have been conducted in accordance with an Institutional Animal Care and Use Committee (IACUC).

Plasmids
The cDNA of human USP9X was from NIH MCG 428. Flag-tagged and Myc-tagged versions of USP9X-wild type (USP9X-WT) were constructed by PCR using the MCG clone as the template and cloned into pCMV vector (Promega). Myc-tagged enzyme defective mutant, USP9X-H1871A, was generated by introduction of histidine to alanine residue (1871) of the enzyme catalytic domain by PCR. The HA-tagged Ubiquitin plasmid was purchased from Addgene (#17608). Flag-tagged LATS2 fragments and HA-tagged USP9X fragments were constructed by PCR using pCMV.Flag-LATS2 and pCneo-HA-USP9X as a template, respectively. All the rest of plasmids were described previously (19–22). Cre cDNA was cloned into pLVXpuro from Clontech.

Antibodies and reagents
USP9X (#A301-350A) and LATS (#A300-479A) antibodies were purchased from Bethyl Laboratories Inc. YAP (#4912), phospho-YAP127 (#4911), TAZ (#4883), MST1 (#3682), MST2 (#3952), and Pan-TEAD (#13295) antibodies were from Cell Signaling Technology. KIBRA (#LS-C175353) antibody was purchased from LifeSpan and AMOT antibody was from Santa Cruz Biotechnology and Abnova as previously described (19, 20). Fibronectin (#610077), vimentin (#550153), and E-cadherin (#610404) were from BD Biosciences. Anti-Flag antibody was from Sigma, anti-HA and anti-Myc antibodies were purchased from Roche. Immunohistochemistry analyses were completed using USP9X (#55054-1-AP) antibody purchased from Proteintech, LATS1/2 (#ab70565) from Abcam and YAP/TAZ (#8418) from Cell Signaling Technology. Western blot analyses were performed as described previously (23). Mouse anti-HA-agarose antibody was from Sigma. Anti-c-Myc monoclonal agarose conjugate was purchased from Nacalai Tesque Inc., and E2 view red anti-Flag M2 affinity gel was from Sigma. MG-132 proteasome inhibitor was obtained from Calbiochem. Nuclear and cytoplasmic fractions were prepared using NE-PER Nuclear and Cytoplasmic Extraction reagents (#78833, Thermo Scientific).

Gel filtration analysis
1.2 mg of HEK293 cell lysate was fractionated using the Superose 6 HR 10/30 column (GE Healthcare), using the ÄKTA<sup>™</sup> Purifier 10 FPLC system (GE Healthcare). Fractionation was performed in PBS at 4°C. Flow rate was 0.3 ml/min and fractions of 0.6 ml each were collected. The fractions were precipitated with trichloroacetic acid (TCA), resolved by SDS-PAGE and transferred to PVDF membrane (Millipore) for subsequent immunodetection.

Anchorage-independent growth in soft agar, cell motility and invasion assays (Transwell assays), retrovirus generation, infection, immunoprecipitation and mass spectrometry, and data analysis
The protocols were described previously (19–23).

Lentivirus generation and infection
293FT cell line and ViraPower Packaging Mix for lentivirus production were purchased from Thermo Fisher Scientific and lentiviruses were produced according to their instruction.

RNA isolation and real-time PCR
The protocols were carried out as previously described (19, 21). TaqMan probes used in this study were purchased from Thermo Fisher Scientific; USP9X, #Hs01126052; CTGF, #Hs00170014; CYR61, #Hs00155479; TEAD1, #Hs01733559; TEAD2, #Hs00366217; TEAD3, #Hs00243231; TEAD4, #Hs01125032 and 18S, #Hs00306361.

siRNA
Transfections were carried out as previously described (22). The following siRNAs were purchased from Dharmaco: Control (nontarget), #D-001810-10-50; USP9X, #L-006099-00-0005; YAP, #L-012200-00-0005; TAZ, #L-016083-00-0005; TEAD1, #J-012603-05; TEAD2, #J-012611-10; TEAD3, #J-012604-08; TEAD4, #J-019570-09.

shRNA-mediated knockdown
The sequences for the sense oligonucleotides for the knockdown constructs were as follows: USP9X shRNA #1, CCGTAGAGATGCCAGAGAAC; USP9X shRNA #2, CCAAAGGAATGCTTGGAGAT; USP9X shRNA #3, GAGAGATATCAGTCTGTA; USP9X shRNA #4, GGTTGCTGATCCAGTAAA; TEAD1 shRNA GAAGAAGATCAGTAG; TEAD2 shRNA GAAGCCATTCCTACAGACA;
Deubiquitination assay

HEK293 cells were transiently transfected with the indicated plasmids and treated with MG-132 (40 μmol/L) for 8 hours prior to cell lysis. Subsequently, cells were washed with ice-cold PBS and lysed in ice-cold lysis buffer (150 mmol/L NaCl, 50 mmol/L Tris-HCL at pH 7.4, 0.5% NP-40, protease inhibitor cocktail [Roche]). Next, cell lysates were cleared by a spin (13,000 rpm, 10 min, 4°C) and a fixed amount of whole-cell lysates was incubated with the appropriate agarose conjugated antibodies overnight. The agarose resin was washed twice with lysis buffer with 500 mmol/L NaCl, followed by three times with lysis buffer. Deubiquitination was assessed by subjecting the samples to Western blot analysis with anti-HA antibodies (ubiquitin).

Immunohistochemistry

Human pancreatic cancer tissue arrays (#PAN801, #PA961b, US Biomax Inc.) and pancreatic cancer patient tissue samples (Singapore Health Services Pte Ltd.) were used to examine protein expression of USP9X, LAT51/2 kinases, and YAP/TAZ in normal and cancer tissues. Immunohistochemistry was done using Leica Bond Polymer Refine Detection Kit. The slides were deparaffinized in Bond Dewax Solution and rehydrated through 100% Bond Polymer Reagent, and antigen retrieval was performed with 1X Bond Epitope Retrieval Solution for 40 minutes at 100°C of ethanol to 1X Bond Wash Solution followed by antigen retrieval using Bond Epitope Retrieval Solution for 40 minutes at 100°C. After cooling to room temperature, the slides were rinsed with 1X Bond Wash Solution for four times. Subsequently, endogenous peroxidase was blocked for 15 minutes in 3–4% H2O2. After rinsing with Bond Wash Solution, the slides were blocked for 30 minutes in 10% goat serum and incubated with the primary antibody for 15 minutes at room temperature. Next, the slides were washed five times in 1X Bond Wash Solution followed by 5 minutes incubation with the polymer. After series of washes in 1X Bond™ Wash Solution, Bond Mixed DAB Reine was applied for 7 minutes and rinsed off in deionized water to terminate DAB reaction. The nuclei were counterstained with hematoxylin for 5 minutes. Subsequently, slides were dehydrated and mounted in synthetic mounting media. Tissues were digitalized using 3D Histech Pannoramic 250 Flash II slide scanner and analyzed using ImageJ and CaseViewer software. Protein expression levels were scored as grades accordingly to the immunostaining intensity. Tissue arrays (#PAN801, #PA961b) were scored as three grades (negative, weak, and strong expression), whereas samples derived from pancreatic cancer patients were scored as four grades (0, negative expression; 1, weak expression; 2, moderate expression; 3, strong expression). The studies were conducted in accordance with the International Ethical Guidelines for Biomedical Research Involving Human Subjects (CIOMS) and were approved by an institutional review board (SingHealth Institution). SingHealth Institution obtained consents from the patients.

Extraction of clinical and microarray gene expression data from pancreatic cancer patient datasets

One pancreatic cancer patient dataset, GSE21501 (24), available in the Gene Expression Omnibus (GEO) Database (http://www.ncbi.nlm.nih.gov/gds) was identified in this study based on searching the key words “pancreatic cancer” and “survival” with a return with the highest number of samples, available gene expression array data and patient survival data. The GEO website has standardized URLs for its individual datasets, for example, the overall summary information about the microarray dataset GSE21501 can be accessed at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21501. The Series Matrix File(s), which contain the expression values for each gene (probeset) can be accessed with the URL ftp://ftp.ncbi.nih.gov/pub/geo/DATA/seriesMatrix/GSE21501. The file in gzip format was then unzipped to the tab-delimited text format, which contains detailed information for statistical analysis. The GSE21501 dataset is the largest pancreatic cancer patient dataset in the GEO database comprising 102 patients. Microarray gene expression data were retrieved from the data matrix deposited to the GEO database by the original authors. R scripting was used to extract the expression values of genes (probesets) of interest and the clinical data from the data matrix downloaded from GEO.

Correlations of gene expression levels and clinical data

All statistical analyses were performed using SPSS19.0. The associations between expression levels of genes were analyzed by Spearman’s rank test. ANOVA was used to test the differential gene expression between groups of patients. Kaplan–Meier survival analysis was performed to investigate the association between expression and survival; results of Kaplan–Meier analysis were compared by log-rank test for statistical analysis. P < 0.05 was considered significant in all statistical analyses.

Results

USP9X interacts with Hippo pathway components

To understand how the protein stability of the Hippo pathway components is regulated, we identified the ubiquitin E3 ligases and deubiquitinating enzymes from the protein interaction network of the Hippo pathway generated in our group. Among them, the deubiquitinating enzyme, USP9X, turned out to be one of the top confidence interactions (Fig. 1A, left). USP9X was also identified from protein interaction network of the Hippo pathway by another group (25). To verify whether USP9X truly interacts with the Hippo pathway, we expressed HA-tagged version of different Hippo pathway components in HEK293 and checked if endogenous USP9X is indeed associated with each of them. Figure 1A, right, shows that among the 13 Hippo components tested, LATS2 and WW45 interact with USP9X strongly. AMOT family members (AMOT, AMOTL1, and AMOTL2) and KIBRA also interact with USP9X, but only weakly. To further examine if USP9X forms complexes with any of these interactors, we used gel filtration analysis through fast protein liquid chromatography (FPLC). Most of the USP9X was found to form large complexes (>669 kDa) with LATS, lesser with WW45, KIBRA, AMOT, YAP, and TAZ (Fig. 1B). AMOT was shown recently to be a USP9X-interacting protein (26, 27). Because LATS, KIBRA, and WW45 are found as new interactors of USP9X, we performed reciprocal immunoprecipitation experiments. Indeed, USP9X was found in the immunoprecipitates, indicating that LATS, WW45, and KIBRA are genuine interactors of USP9X, with LATS showing the strongest interaction (Fig. 1C–E). These results indicate that USP9X may regulate the Hippo pathway through its strong interactions with LATS as well as with WW45, KIBRA, and AMOT. Subsequently, N- and C-terminal-truncated USP9X and LATS2 mutants were constructed to map the binding region for LATS2 (Fig. 1F) and USP9X (Fig. 1G), respectively. The results suggest that the first 600 amino acids of USP9X are mostly responsible for interaction.
USP9X interacts with Hippo pathway components. A, USP9X was identified as the top interactor of KIBRA. The chart for the unique peptide counts is presented (left). HA-tagged components of the Hippo pathway were transiently expressed in 293 cells and cell lysates were immunoprecipitated with an anti-HA antibody. The coprecipitation of endogenous USP9X with various components was done using USP9X antibody (right). Fractions starting from A11 to C11 are shown. Only LATS was found to be strongly co-migrated in the same fractions as USP9X (fractions B5–B6).

B, FPLC analysis of 293 cell lysate. Forty-five fractions (A1–15, B1–15, and C1–11) were collected and proteins combined from two fractions were pooled and run on each lane. Fractions starting from A1 to C11 are shown. Only LATS was found to be strongly co-migrated in the same fractions as USP9X (fractions B5–B6).

C–E, Analytic reciprocal communoprecipitation experiments showing the interaction of USP9X with LATS2, WW45, and KIBRA, with LATS2 being the strongest interactor of USP9X. F, Mapping of the LATS2-interacting domain of USP9X. G, Mapping of the USP9X-interacting domain of LATS2.
with LATS2, whereas the USP9X-interacting domain of LATS2 is mainly present between 300 and 600 amino acids. Although other regions of the proteins may also contribute to the bindings, the interactions were less significant. Because USP9X interacts strongly with LATS and LATS kinases are involved in the direct regulation of downstream targets YAP and TAZ, in this report, we concentrated our study on the regulation of LATS by USP9X.

USP9X stabilizes Hippo pathway upstream components

USP9X belongs to the USP family of deubiquitinating enzymes and stabilizes proteins by preventing their proteasomal degradation (13). To investigate the effect of USP9X on the protein stability of Hippo components, USP9X was knocked down by siRNA in immortal pancreatic duct epithelial HPDE6 cells followed by the investigation of the protein levels of Hippo members. HPDE6 were chosen because USP9X was originally identified as a tumor suppressor in pancreatic tissues (14) and interaction of USP9X with the Hippo pathway suggests a potential molecular mechanism for its tumor suppressor role. Following the knockdown of USP9X in HPDE6 cells, the protein levels of LATS kinase, WW45, and phospho-YAP were significantly downregulated (Fig. 2A, left). USP9X knockdown was additionally performed in MCF10A cells (Fig. 2A, right) with similar results to HPDE6. In MCF10A, KIBRA was significantly downregulated as well. These results indicate that USP9X is important for the maintaining stability of Hippo components especially LATS, WW45, and KIBRA.

In addition, we screened for shRNA, which could be used for stable knockdown of USP9X. As shown in Fig. 2B, out of four shRNAs designed for USP9X, shRNA#3 and shRNA#4 showed significant downregulation of LATS in MCF10A. shRNA#3 was chosen to knockdown USP9X stably in cells. As expected, sustainable knockdown of USP9X in MCF10A cells significantly downregulates LATS, WW45, and KIBRA (Fig. 2C). Subsequently, the subcellular localization of YAP and TAZ was investigated. USP9X knockdown MCF10A cells were fractionated into nuclear and cytoplasmic fractions. As shown in Figure 2C, right, most of the YAP and TAZ is found in the nucleus, much less in the cytoplasm and this is consistent with the fact that there is less phosphorylated YAP in all cell types with the USP9X knockdown by either siRNA or shRNA (YAP127 panels). In our previous study, we have shown that nuclear form of TAZ (S89A) is less stable and

---

**Figure 2.**

USP9X stabilizes upstream Hippo components. A, Knockdown of USP9X by siRNA in HPDE6 (left) and MCF10A (right) cells resulted in downregulation of LATS, WW45, and phospho-YAP. Downregulation of KIBRA was seen in MCF10A cells. B, Screening of USP9X shRNA in MCF10A cells. Co-downregulation of LATS with USP9X was seen with shRNA #3 and #4. C, MCF10A were stably knocked down with USP9X shRNA #3. LATS, WW45, KIBRA, and phospho-YAP were downregulated (left) and TAZ was significantly translocated to the nucleus (right) in response to USP9X silencing. D, LATS was downregulated in Floxed USP9X MEF cells after Cre expression. E and F, Knockdown of USP9X by siRNA (E) and shRNA (F) in various cell lines resulted in upregulation of YAP/TAZ target genes, CTGF and CYR61, as accessed by real-time PCR.
expressed less as compared to wild type (22). Furthermore, Pan D lab has also shown that nuclear form of YAP is less stable (28). This might explain why after the USP9X knockdown, YAP/TAZ was activated and translocated to the nucleus, whereas the total amount of YAP/TAZ was reduced. To further corroborate the results, depletion of USP9X by Cre resulted in a decrease of endogenous LATS significantly, verifying that the expression of USP9X and LATS is positively correlated (Fig. 2D). Unexpectedly, the YAP and TAZ expression was downregulated. We think it is due to negative feedback regulation of the Hippo pathway, especially in the primary cells. The negative feedback is mediated through LATS/YAP/TAZ/TEAD as shown previously (28, 29). When cells express highly activated YAP and TAZ, LATS is activated to counter the hyperactivity of YAP and TAZ. To sustain homeostasis of cells, YAP and TAZ expression is controlled, especially in primary cells where the feedback is intact. In cancer cells, this negative feedback might be compromised.

Taken together, these results suggest that downregulation of USP9X leads to destabilization of LATS and other Hippo components, which in turn results in translocation of YAP and TAZ to the nucleus.

Knockdown of USP9X enhances expression of YAP/TAZ target genes CTGF and Cyr61

We also investigated if the increase in nuclear YAP and TAZ due to USP9X knockdown would result in the increment of their well-documented target genes, CTGF and Cyr61. Because the antibodies for CTGF and Cyr61 are not specific in our hands, their mRNA expression was analyzed by quantitative PCR. Figure 2E shows that depletion of USP9X by siRNA in HPD6e and MCF10A induced CTGF and Cyr61 mRNA expression between three- to five-fold. A similar trend was observed in MCF10A cells stably expressing USP9X shRNA#3, CTGF, and Cyr61 mRNA levels were upregulated (Fig. 2F). These results suggest that USP9X indeed acts upstream of YAP and TAZ to suppress their activity.

USP9X deubiquitinates Hippo pathway components

USP9X may potentially stabilize Hippo pathway components through its deubiquitinating activity to prevent their proteasomal degradation. In order to investigate whether USP9X is able to deubiquitinate the Hippo pathway components LATS, WW45, KIBRA and AMOT, ubiquitination and deubiquitination assays were performed. The increasing amount of USP9X was expressed in 293 followed by the assessment of endogenous ubiquitinated LATS, AMOT, KIBRA, and WW45 in the presence of USP9X. Furthermore, deubiquitination assays were performed for AMOT, KIBRA, and WW45, the other USP9X substrates. Fig. 3B–D shows that there are less endogenous ubiquitinated AMOT, exogenous Kibra (C), and WW45 (D). E, Knockdown of USP9X augmented ubiquitinated LATS2. F, Enzyme-defective USP9X (Myc-USP9X-H1871A) lost the ability to protect LATS2 from ubiquitination.
knockdown 293 cells, as compared to that of control cells (Fig. 3E). To verify that the deubiquitinating enzyme activity of USP9X is indeed responsible for the stability and deubiquitination of the Hippo components, we constructed enzyme defective mutant of USP9X (USP9X-H1871A) by changing the crucial amino acid 1871 histidine to alanine of USP9X. Fig. 3F shows that USP9X-H1871A did loose deubiquitinating activity towards LATS2. These results indicate that USP9X stabilizes Hippo pathway components by deubiquitination and prevention of their proteasome-mediated degradation.

Figure 4.
Knockdown of USP9X leads to oncogenic transformation. A, Knockdown of USP9X by shRNA #3 and #4 in MCF10A cells resulted in cell morphological change reminiscent of EMT. B, Increased expression of fibronectin, vimentin, and decreased expression of E-cadherin in USP9X knockdown MCF10A cells. C, Increased invasion activity of USP9X shRNA #3 MCF10A cells in Matrigel Transwell assays. D, USP9X shRNA #3 MCF7 cells displayed enhanced anchorage-independent growth in soft agar. E, Three-dimensional culture of USP9X shRNA #3 MCF10A in Matrigel. USP9X shRNA #3 MCF10A acini have enlarged and disorganized morphology. F, USP9X and LATS expression is highly regulated by growth signal. MCF10A grown in different percentage of serum were assessed for the expression of USP9X, LATS, AMOT, YAP, and TAZ.
USP9X knockdown cells are oncogenic and knockdown of YAP, TAZ or TEAD2, and expression of LATS kinase rescue the phenotypes

MCF10A cells stably expressing USP9X shRNA#3 and shRNA#4 displayed elongated, fibroblastic morphology, reminiscent of epithelial to mesenchymal transition (EMT; Fig. 2B and 4A). Indeed, EMT markers fibronectin and vimentin were increased, whereas the epithelial marker E-cadherin was downregulated significantly in USP9X shRNA#3 MCF10A cells compared to the control cells (Fig. 4B). Moreover, Transwell migration and invasion assays were used to investigate if the USP9X knockdown MCF10A cells acquired these characteristics. Fig. 4C shows that after knockdown of USP9X in MCF10A, cell invasion was increased, whereas migration was not obviously different from the control cells. Furthermore, knockdown of USP9X in MCF7 breast cancer cells significantly increased the number and the sizes of soft agar colonies in an anchorage-independent growth assay (Fig. 4D). In addition, a three-dimensional acini assay in Matrigel was performed using USP9X knockdown MCF10A (16). The acini formed by MCF10A control cells in Matrigel were well-organized, round, and smooth (Fig. 4E), but the acini formed by USP9X knockdown MCF10A in Matrigel were enlarged and disorganized, indicating that USP9X knockdown cells were transformed.

Next, the correlation of USP9X and LATS in serum-starved condition was examined. As shown in Fig. 4F, in 1% serum condition (lane 2), expression of USP9X was significantly increased as compared to the complete media condition (lane 1). The upregulation of USP9X was accompanied by increased LATS expression verifying their positive correlation under reduced serum conditions. Strong expression of USP9X and LATS was accompanied by the reduced YAP and TAZ expression. In cells grown in 5% serum, the expression of USP9X and LATS were, like AMOT, downregulated to the level of that of the cells grown in complete media with accompanying increase of YAP and TAZ. These results indicate that USP9X and LATS expression, like Hippo pathway, are highly regulated by growth signal.

To show that USP9X indeed works with Hippo pathway to inhibit YAP, TAZ, and their transcription factor TEAD, we investigated whether the upregulated YAP/TAZ target genes, CTGF and Cyr61, in USP9X knockdown cells could be rescued by either knockdown of YAP and TAZ, or by reduced YAP and TAZ expression with Hippo components. Fig. 6A shows that USP9X knockdown cells in Matrigel were transformed, indicating that USP9X does not function alone to inhibit oncogenic growth in cells by stabilization of Hippo components especially LATS to restrict the activity of TAZ and YAP.

USP9X expression is positively correlated with LATS kinase and negatively with YAP/TAZ in cancer cells and cancer tissues

USP9X was identified as a tumor suppressor in pancreatic tissues (14) and we have shown that USP9X is able to stabilize Hippo pathway components especially LATS kinase to restrict YAP/TAZ/TEAD activity. This suggests that USP9X could act as a tumor suppressor via the Hippo pathway to inhibit cell growth and proliferation. Subsequently, a panel of pancreatic cancer cell lines was used to examine the potential correlation of USP9X expression with Hippo components. Fig. 6A shows that USP9X protein level is lower in invasive cells, BxPC3, CFPAC1, and Panc1, than in nontransformed HPDE6 cells. The expressions of LATS and WW45 show similar profiles to USP9X. YAP/TAZ protein expression is upregulated in a number of cancer types (4, 6, 23, 30). TAZ expression is significantly higher in CFPAC1 and Panc1 cells, but barely detectable in HPDE6 and in the weakly invasive BxPC3 cells. Furthermore, CTGF and Cyr61 (Fig. 6B) are also highly expressed in CFPAC1 and Panc1 cells. The positive correlation of USP9X with Hippo pathway component LATS, WW45 and negative correlation with YAP and TAZ and their target genes was revealed in this pancreatic cell line panel.

USP9X is also oncogenic in some cell types (31, 32), but as shown in Fig. 6C, USP9X expression is significantly lower in triple-negative breast cancer cells, Hs578T, BT549, and MDA-MD-231 and MCF10A cells but expressed more in weakly invasive cell lines MCF7, SKBR3, BT-474, ZR75.1, and SKBR3. The LATS expression profile is similar to USP9X, and both USP9X and LATS expression is inversely correlated with those of YAP and TAZ especially TAZ, which is highly expressed in invasive breast cells Hs578T, BT-549, and MDA-MB-231 (23). Taken all together, these results indicate that USP9X may cooperate with Hippo pathway component LATS to inhibit YAP and TAZ, especially TAZ, in pancreatic and breast cells.

Next, we examined their expression levels in pancreatic tissue microarrays (Fig. 6D) and consecutive tissue sections obtained from pancreatic cancer patients (Fig. 6E). USP9X, LATS, YAP/TAZ antibodies were verified to be specific after knocking down each of them in the cells by their respective siRNA (Fig. 6E, top). Notably, negative expression of USP9X was observed in 65.4% (66 of 101) of pancreatic tumors, 3.9% (2 of 52) of cancer adjacent normal and 18.2% (4 of 22) of normal pancreatic tissues, demonstrating a significant correlation between USP9X downregulation and pancreatic tumorigenesis (Fig. 6D, top right). Moreover, negative
Figure 5. YAP/TAZ and TEAD are downstream mediators of USP9X. A, The activation of YAP/TAZ target genes, CTGF and Cyr61, due to USP9X knockdown could be rescued by knockdown of YAP/TAZ. The mRNAs of CTGF and Cyr61 were accessed by RT-PCR. B, The enhanced anchorage-independent growth by the USP9X knockdown in MCF7 cells could be rescued by knockdown of YAP and TAZ. C and D, TEAD2 was identified as one of the major TEAD isoforms downstream of USP9X. The activation of YAP/TAZ target genes, CTGF and Cyr61, due to USP9X knockdown could be rescued by knockdown of TEAD2. siRNA of the four TEAD isoforms could be effectively knocked down in cells (C) and TEAD2 knockdown could significantly suppress increased CTGF and Cyr61 mRNA in USP9X knockdown cells (D). E, TEAD2 is able to rescue the anchorage-independent growth of USP9X knockdown cells. F, LATS2 is able to rescue the YAP and TAZ expression induced by the USP9X knockdown.
USP9X and LATS are positively correlated in cancer cell lines and pancreatic cancer tissues. **A**, Decreased USP9X, LATS, WW45 and increased YAP, TAZ protein expression was detected in pancreatic cancer cells. **B**, Increased mRNA levels of CTGF (left) and Cyr61 (right) in pancreatic cancer cells quantified by RT-PCR. **C**, USP9X and LATS protein levels were downregulated in triple-negative breast cancer cells. **D**, IHC staining of USP9X and LATS in normal and pancreatic cancer tissue microarrays (left). USP9X and LATS protein expression was predominantly negative in pancreatic cancer tissues (right). **E**, Characterization of USP9X, LATS, and YAP/TAZ antibodies used for IHC tissue staining (top). USP9X and LATS were expressed weakly as opposed to strong YAP/TAZ expression in analogous tissue sections derived from pancreatic cancer patients (bottom). **F-H**, Analysis of USP9X, YAP, and YAP/TAZ target genes using pancreatic cancer patient dataset, GSE2501. **F**, Tumors expressing USP9X lower than the lower quartile cut off had shorter life-span. **G and H**, Positive correlation of YAP and its target gene CTGF only observed in the low expression of USP9X.
expression of LATs in the same tissue microarrays was detected in 53.3% (34 of 101) of pancreatic tumors, 3.9% (2 of 52) of cancer adjacent normal and 9.1% (2 of 22) of normal pancreatic tissues (Fig. 6D, bottom right). YAP and TAZ expression levels and activation was previously reported to be markedly higher in pancreatic cancer cells and tissues (33, 34). Collectively, these findings suggest a possible link between low USP9X, LATs expression and high YAP/TAZ expression in human pancreatic tumors. Moreover, the analysis of the consecutive sections obtained from pancreatic cancer patients confirmed this relationship. Fig. 6E shows that the expression profiles of USP9X in pancreatic cancer tissues are also negatively correlated with that of YAP/TAZ, and positively correlated with LATs1/2.

In addition, in pancreatic cancer patient dataset (GSE21501), as shown in Table 1, by Spearman’s rank test, we found that expression level of YAP1 was significantly positively correlated with the expression levels of TEAD2 (r = 0.351, P < 0.001) and TEAD4 (r = 0.257, P = 0.00), whereas the expression level of USP9X was significantly negatively correlated with YAP1 (r = −0.217, P = 0.029), TEAD2 (r = −0.328, P = 0.001), and TEAD4 (r = −0.397, P < 0.001). These results suggest that YAP1, TEAD2, and TEAD4 may be regulated in an opposite direction to that of USP9X.

By Kaplan–Meier analysis, we found that 25% lowest USP9X expressing patients had a mean survival time of 14.2 months, which was significantly shorter than the mean survival time of 26.6 months for the rest of patients whose tumors expressed a higher level of USP9X (P = 0.017; Fig. 6F). This result suggests that a high level expression of USP9X may be a favorable prognostic marker for pancreatic cancer. Moreover, a significant positive association between YAP1 and its downstream target, CTGF, could only be observed in a background where USP9X was expressed at a low level (P = 0.01) but not in a background where USP9X was expressed at a high level (P = 0.22; Fig. 6G and H). These results suggest that a high level expression of USP9X may impair YAP activity.

Table 1. GSE21051 dataset (n = 102) correlations between YAPI, USP9X, and TEADs

<table>
<thead>
<tr>
<th>Spearman’s r</th>
<th>YAPI</th>
<th>USP9X</th>
<th>TEAD1</th>
<th>TEAD2</th>
<th>TEAD3</th>
<th>TEAD4</th>
</tr>
</thead>
<tbody>
<tr>
<td>YAPI</td>
<td>1.000</td>
<td>−0.217</td>
<td>0.433</td>
<td>0.358</td>
<td>0.202</td>
<td>0.257</td>
</tr>
<tr>
<td>P value</td>
<td>0.029</td>
<td>0.091</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>0.042</td>
<td>0.001</td>
</tr>
<tr>
<td>USP9X</td>
<td>−0.217</td>
<td>1.000</td>
<td>−0.058</td>
<td>−0.328</td>
<td>−0.031</td>
<td>−0.397</td>
</tr>
<tr>
<td>P value</td>
<td>0.029</td>
<td>0.397</td>
<td>0.001</td>
<td>0.001</td>
<td>0.001</td>
<td>0.001</td>
</tr>
<tr>
<td>TEAD1</td>
<td>0.433</td>
<td>−0.058</td>
<td>1.000</td>
<td>0.121</td>
<td>0.160</td>
<td>−0.053</td>
</tr>
<tr>
<td>P value</td>
<td>&lt;0.001</td>
<td>0.559</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TEAD2</td>
<td>0.351</td>
<td>−0.328</td>
<td>0.121</td>
<td>1.000</td>
<td>−0.032</td>
<td>0.407</td>
</tr>
<tr>
<td>P value</td>
<td>&lt;0.001</td>
<td>0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TEAD3</td>
<td>0.202</td>
<td>−0.031</td>
<td>0.160</td>
<td>−0.032</td>
<td>1.000</td>
<td>0.232</td>
</tr>
<tr>
<td>P value</td>
<td>0.042</td>
<td>0.759</td>
<td>0.109</td>
<td>0.749</td>
<td>0.109</td>
<td>0.019</td>
</tr>
<tr>
<td>TEAD4</td>
<td>0.257</td>
<td>−0.397</td>
<td>−0.053</td>
<td>0.407</td>
<td>0.232</td>
<td>1.000</td>
</tr>
<tr>
<td>P value</td>
<td>0.009</td>
<td>&lt;0.001</td>
<td>0.599</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*Correlation is significant at the 0.05 level (two-tailed).
*aCorrelation is significant at the 0.01 level (two-tailed).

Discussion

In this study, we identified USP9X deubiquitinating enzyme as a synergizing component of the Hippo pathway that interacted with and stabilized LATs kinase, WW45, KIBRA, and AMOT to negatively regulate YAP/TAZ, transcription factor TEAD, and their target genes to suppress tumor growth.

The posttranslational modifications such as phosphorylation are well known to play an essential role in the regulation of this tumor suppressive pathway. Nonetheless, regulation through the covalent attachment of the ubiquitin molecule by ubiquitin ligases or its removal through deubiquitinating enzymes has not been explored in great detail so far. In recent times, increasing number of reports describing the regulation of the Hippo pathway through ubiquitination has emerged (8, 10, 35). However, none of the deubiquitinating peptidases were ascribed to the Hippo pathway regulation. Through proteomics approach, we identified USP9X as one of the candidate deubiquitinating enzymes regulating the Hippo pathway. During the preparation of the manuscript, two other groups reported USP9X as an interactor of Hippo components (26, 27). In these two reports, USP9X was found to regulate and cooperate with Angiomotin family members, though with opposite effects on Hippo pathway. These findings further verify the importance of USP9X in the Hippo pathway.

Strikingly, we found USP9X to interact with the four fundamental components of the Hippo pathway. FPLC analysis revealed that among these interactors only LATs was found to interact strongly with USP9X in the same fractions. Through immunoprecipitation assays, LATs and WW45 were also demonstrated to be the two strongest interactors of USP9X. Even though USP9X was shown to deubiquitinate and stabilize all of the four Hippo components, LATs and WW45 were revealed to be the most responsive substrates for USP9X in our experiments. As USP9X is a large protein of ~270 kDa, it could potentially simultaneously interact with all the four Hippo components. In order to maximize the Hippo signaling effect, it is likely that USP9X associated with more than one Hippo components to stabilize them and exert their inhibition on the downstream effectors YAP/TAZ/TEAD.

One issue that is important in this study is the feedback regulation of the Hippo pathway. Prolonged USP9X knockdown will lead to downregulation of YAP/TAZ/TEAD target genes CTGF and Cyr61 instead of their upregulation. It is also true for LATs; prolonged USP9X knockdown will result in an increase of LATs or vice versa. LATs kinase has been previously shown to be upregulated after YAP or/tand TAZ depletion (29, 36). This feedback loop might explain why there is a conflicting outcome after USP9X knockdown from the other two studies (26, 27).

Disregulation of the Hippo pathway signaling has been previously implicated in pancreatic cancer. YAP and TAZ have been revealed to play essential roles in the advancement of pancreatic
tumors (33, 34, 37). Interestingly, there are not many reports suggesting a possible role for LATS in pancreatic tumorigenesis. This kinase has been previously implicated to function as a tumor suppressor in other cancer types including breast cancer, hepatocellular carcinoma and ovarian cancer (9, 38, 39). However, not many studies conducted a comprehensive investigation of its importance in pancreatic cancer. In this study, we demonstrated that USP9X expression was markedly downregulated in pancreatic cancer cells and in pancreatic tumors. Furthermore, the protein expression of USP9X and LATS was shown to be positively correlated in normal and cancerous tissue samples. Moreover, we hypothesized that USP9X regulation of WW45 adaptor protein may also play a crucial role in pancreatic cancer. Expression levels of these two proteins were demonstrated to be positively correlated in pancreatic cells. In conjunction with our findings, the lower expression of WW45 has been recently linked to pancreatic ductal adenocarcinoma progression further supporting our conclusions (40). In addition, we extended our studies to the analysis of mRNA dataset in which USP9X was shown to be negatively correlated with YAP, TEAD, and CTGF, but not TAZ and LATS kinase. TAZ has been previously demonstrated to function as an oncprotein in a number of cancer types and its expression was established to be regulated at the protein level, but not mRNA level (23). This might explain why in the mRNA dataset findings, there was no negative correlation between TAZ and USP9X. This might also explain why LATS, although positively correlated with USP9X in pancreatic cells and tissues at the protein level, does not show a positive correlation with USP9X in the results obtained from mRNA dataset.

Another important finding from this study is that the protein expression level of USP9X and LATS is downregulated in highly invasive breast cancer cells as compared to weakly invasive cells and their expression is in reversed relationship with TAZ, which has been already shown to be upregulated in these highly cancerous cells (23). The panel of breast cancer cell lines used in this report has been previously established to recapitulate characteristics of the breast cancer disease (41, 42). Despite the fact that USP9X has been earlier reported to be overexpressed in breast cancer tissues (43), the results revealed in this report suggest that USP9X might indeed act as tumor suppressor similarly to its function in pancreatic cells and tissues. Further investigation of clinical samples of invasive breast carcinoma will provide a better understanding of the USP9X regulation of the Hippo pathway components and its role in this deadly disease.

In conclusion, we have identified one of the first deubiquitinating enzymes to stabilize core Hippo component LATS kinase and to indirectly stimulate YAP, TAZ and transcription factor TEAD. Strikingly, USP9X not only was revealed to regulate LATS kinase but also was demonstrated to interact and stabilize WW45, KIBRA, and AMOT, the other essential members of the Hippo pathway. LATS kinase and WW45 adaptor protein are implicated as tumor suppressors in various cancers and a number of oncogenic E3 ubiquitin ligases have been found to destabilize their protein levels and to alter their functions, resulting in cell transformation and further tumorigenesis. USP9X might act as a deubiquitinating enzyme opposing the effect of E3 ligases in order to stabilize LATS kinase and WW45, therefore, promoting their tumor suppressive roles. There are certainly more deubiquitinating enzymes and ubiquitin ligases regulating the Hippo pathway components yet to be discovered. Further investigation of their functional interactions and implications in the progression of various tumors will hopefully provide valuable insights for the future cancer therapeutics.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: A. Toloczko, S.A. Wood, W. Hong, S.W. Chan Development of methodology: A. Toloczko, Y.S. Ong, W. Hong, S.W. Chan Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Toloczko, H.-F. Yuen, Q. Wen, Y.S. Ong, S.W. Chan Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A. Toloczko, H.-F. Yuen, Y.S. Ong, A. Alli Shaik, J. Gunaratne, S.W. Chan Writing, review, and/or revision of the manuscript: A. Toloczko, H.-F. Yuen, Q. Wen, Y.S. Ong, J. Gunaratne, S.W. Chan Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A. Toloczko, F. Guo, P.Y. Chan, A. Alli Shaik, S.W. Chan Study supervision: M.I. Dunne, S.W. Chan Other (supervision of proteomics experiments): J. Gunaratne

Acknowledgments
We thank Magdalene Koh Hui Keng, Khin Sabai, SingHealth Tissue Repository, and Muhammad Kairos Bin Kosnan, Farazeela Binte Mohd Ibrahim, Histopathology Laboratory, Institute of Molecular and Cell Biology, A*STAR, for their generous help with patient tissues and staining.

Grant Support
This work was funded by Agency for Science, Technology and, Research (A*STAR).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received December 22, 2016; revised May 5, 2017; accepted July 7, 2017; published OnlineFirst July 18, 2017.

References
Deubiquitinating Enzyme USP9X Stabilizes LATS Kinase

Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway


Cancer Res  Published OnlineFirst July 18, 2017.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-16-3413

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.